CS 905

Known as: CS-905 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2004
01219892004

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
BACKGROUND AND AIMS Azelnidipine (CS-905) is a novel dihydropyridine calcium antagonist that is known to be excreted in feces. To… (More)
Is this relevant?
1999
1999
Azelnidipine (CS-905) is a long-acting, once-daily, orally-administered calcium channel antagonist which is being jointly… (More)
Is this relevant?
1995
1995
A new 1,4-dihydropyridine derivative, CS-905, currently under development as a Ca antagonist, showed a gradual onset and long… (More)
Is this relevant?
1994
1994
CS-905 is a dihydropyridine calcium channel antagonist which stands out for its prolonged hypotensive effect, and which is… (More)
Is this relevant?
1994
1994
An animal model having both hypertension and reduced renal function was produced by intraperitoneal injection of puromycin… (More)
Is this relevant?
1990
1990
To investigate the central and regional hemodynamics after long-term administration of CS-905, a novel calcium blocker, we… (More)
Is this relevant?
1990
1990
CS-905, (+-)-3-(1-diphenylmethylazetidin-3-yl)5-isopropyl 2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridine-dicarboxy… (More)
Is this relevant?
1989
1989
CS-905 is a novel dihydropyridine calcium blocker. A single oral administration of CS-905 or nicardipine at doses of 0.3-3.0 mg… (More)
Is this relevant?
1989
1989
CS-905 is a potent dihydropyridine calcium blocker that has a gradual and long-lasting antihypertensive action with little… (More)
Is this relevant?